Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts ...
October 1, 2024–Celebrate the magnificence of horses during Horse Week 2024, an online film festival proudly presented by ...
AllianceQUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery 24.10.2024 / 09:30 CET/CESTThe issuer is solely responsible for the content of this ...
Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...
A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...
GlobalData on MSN9d
Boehringer partners WHO Foundation to advance healthcare accessBoehringer Ingelheim, in partnership with the WHO Foundation [an organisation set up to support the World Health Organization ...
The Phase III trials will evaluate survodutide in metabolic dysfunction-associated steatohepatitis (MASH), fibrosis and ...
The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on surv ...
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for survodutide (BI 456906), which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback